SEC Filings
Prothena Research Spending Falls To $8.4 Million — Quarterly Revenue Also Shrinks
The biotech kept its cash-use forecast unchanged and expects an Alzheimer's trial readout in the first half of 2027.
Prothena (PRTA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The biotech kept its cash-use forecast unchanged and expects an Alzheimer's trial readout in the first half of 2027.
SEC Filings
Chad J. Swanson notified Prothena on Friday that he is leaving October 9 to take a leadership role at one of the biotech's own partners.